Neurochase is helping to deliver transformative therapy solutions aimed at tackling life-limiting and life-threatening neurodegenerative diseases.
Established in 2020 by our founder Professor Steven Gill, UK-based Neurochase is a world leading authority in CNS drug delivery.
The company develops state-of-the-art, bespoke and globally-scalable solutions for the pharmaceutical and biotech industries to enable the delivery of gene therapy and other treatments safely and effectively.
Products